Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489370 | 0.94 | LMNA (0.59) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL489619 | 0.91 | LMNA (0.56) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL489570 | 0.81 | LMNA (0.63) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL3527407 | 0.76 | LMNA (0.52) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL489208 | 0.75 | LMNA (0.57) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL490274 | 0.75 | LMNA (0.55) | LMNATSHRALDH1A1SMN1; SMN2POLB | |
| SCHEMBL15976542 | 0.73 | DHFR (0.77) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL10112948 | 0.72 | MEN1 (0.74) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL10113234 | 0.71 | POLB (0.77) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL5340104 | 0.71 | KMT2A (0.86) | LMNATSHRALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687511-B2 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcium channel blockers | PULLELA PHANI KUMAR | 2010-03-30 | — | — | US | claimed |
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | PULLELA PHANI KUMAR | 2008-05-29 | — | — | US | claimed |
| EP-1515723-B1 | SUBSTITUTED DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENT RES FOUNDATION (IN) | 2014-02-12 | — | — | EP | disclosed |
| US-8106062-B1 | Calcium channel blockers | DIAKRON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7687511-B2 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcium channel blockers | PULLELA PHANI KUMAR | 2010-03-30 | — | — | US | disclosed |
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | PULLELA PHANI KUMAR | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | ORAI1, RYR2, RYR1 | LMNA 3818/4885TSHR 4844/4885ALDH1A1 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.